Ten desks. One underwriting standard.
Each market has its own science base, payer logic and capital behaviour. These pages set out how we invest in each, and who to contact.
Hyderabad
Genome Valley and the wider Telangana cluster produce more regulated-market API and vaccine volume than most countries. We underwr…
New York
From New York we run LP relationships, SPV formation and the syndicate work that lets a Series B close without a six-month sponsor…
Los Angeles
Los Angeles and San Diego combine device engineering, genomics and a compute-native founder base. We fund the companies where that…
Singapore
One legal and capital hub, six materially different health systems. We use Singapore to structure regional platforms that can oper…
Tokyo
Japan and Korea hold deep pharma balance sheets and demanding regulators. We invest where a company's value is set by partnering s…
Sydney
Fast ethics approvals, credible data and R&D incentives let Australian and New Zealand companies generate first-in-human evidence …
Abu Dhabi
Sovereign and family capital in Abu Dhabi, Dubai and Riyadh is building domestic health capacity while allocating globally. We sit…
London
The UK and EU produce world-class discovery science and then export it too cheaply. We fund companies willing to hold value throug…
Zurich
Switzerland holds an unusual concentration of pharma decision-makers and patient private capital. We use both: partnering routes f…
São Paulo
Large private payer markets, constrained public systems and rising pharma import substitution. We look for companies that lower co…